A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment

Back to Search
Print
Bookmark Trial

NCT00785772

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Saijyo-shi, Ehime, , Japan
See other locations
Contact
1-800-718-1021
[email protected]com
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Impairment
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20-64 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Japanese epilepsy patients with renal impairment

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- NA

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Renal ImpairmentA Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function
NCT01419041
  1. Anaheim, California
  2. DeLand, Florida
  3. Saint Paul, Minnesota
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal ImpairmentStudy Of Palbociclib (PD-0332991) In Renal Impairment
NCT02085538
  1. DeLand, Florida
  2. Orlando, Florida
  3. Saint Paul, Minnesota
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal ImpairmentPharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function
NCT01740362
  1. Orlando, Florida
  2. New Orleans, Louisiana
  3. New Orleans, Louisiana
  4. Minneapolis, Minnesota
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal ImpairmentA Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment
NCT00785772
  1. Saijyo-shi, Ehime
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment
Official Title  ICMJE A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment
Brief Summary The primary objectives of this study are to evaluate the pharmacokinetics (PK) following administration of gabapentin in Japanese epileptic patients with renal impairment to confirm if there are any clinically relevant differences between the plasma gabapentin concentration simulated by population PK model, which was used for the evidence of the dose adjustment for the patients with renal impairment, and observed plasma gabapentin concentration.
Detailed Description Only one subject was able to be enrolled. Given enrollment challenges to identify additional appropriate subjects, discussion was held with the Japan Pharmaceuticals and Medical Devices Agency (PMDA) and it was agreed with the PMDA to terminate this study. The study was terminated on December 14, 2010. The study was not terminated due to any safety findings.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Renal Impairment
Intervention  ICMJE
  • Drug: Gabapentin
    100-200mg once a day
  • Drug: Gabapentin
    200-500mg once a day
  • Drug: Gabapentin
    400-1000mg (200-500 mg twice a day)
Study Arms  ICMJE
  • Experimental: 1: Patients with Cleatinine Clearance (CLcr) 5-14 mL/min
    Intervention: Drug: Gabapentin
  • Experimental: 2: Patients with CLcr 15-29 mL/min
    Intervention: Drug: Gabapentin
  • Experimental: 3: Patients with CLcr 30-59 mL/min
    Intervention: Drug: Gabapentin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: April 5, 2010)		1
Original Estimated Enrollment  ICMJE
 (submitted: November 3, 2008)		10
Actual Study Completion Date  ICMJE April 2010
Actual Primary Completion Date April 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Japanese epilepsy patients with renal impairment

Exclusion Criteria:

  • NA
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 20 Years to 64 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00785772
Other Study ID Numbers  ICMJE A9451169
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. )
Study Sponsor  ICMJE Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP